Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England.
Acute otitis media
Pneumococcal conjugate vaccine
Recurrent AOM
United Kingdom
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
30 01 2023
30 01 2023
Historique:
received:
06
09
2022
accepted:
03
01
2023
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
2
2
2023
Statut:
epublish
Résumé
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2006 and the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010 in the UK. PCVs are active immunization for the prevention of invasive disease, pneumonia and acute otitis media (AOM) caused by Streptococcus pneumoniae in children. The aim of this observational study was to estimate incidence rates (IRs) of AOM in children ≤17 years from 2003 to 2019 in England, before and after the introduction of pneumococcal conjugate vaccines (PCVs). AOM episodes were identified using Read diagnosis codes in children aged ≤17 years in the Clinical Practice Research Datalink (CPRD) Gold database from 2003 to 2019. Annual IRs with 95% confidence intervals (CI) by age group were calculated as the number of episodes/person-years (PY) at risk. Interrupted time series analyses were conducted to estimate incidence rate ratios (IRR) across post-PCV7 (2007-2009), early post-PCV13 (2011-2014) and late post-PCV13 (2015-2019) periods compared to the pre-PCV7 period (2003-2005) using generalized linear models. From 2003 to 2019, 274,008 all-cause AOM episodes were identified in 1,500,686 children. The overall AOM IR was 3690.9 (95% CI 3677.1-3704.8) per 100,000 PY. AOM IRs were highest in children aged < 5 years and decreased by age; < 2 years: 8286.7 (95% CI 8216.8-8357.1); 2-4 years: 7951.8 (95% CI 7902.5-8001.4); 5-17 years: 2184.4 (95% CI 2172.1-2196.8) (per 100,000 PY). Overall AOM IRs declined by 40.3% between the pre-PCV7 period and the late-PCV13 period from 4451.9 (95% CI 4418.1-4485.9) to 2658.5 (95% CI 2628.6-2688.7) per 100,000 PY, and across all age groups. IRRs indicated a significant decrease in AOM IRs in all the post-vaccination periods, compared to the pre-PCV7 period: post-PCV7 0.87 (95% CI 0.85-0.89), early post-PCV13 0.88 (95% CI 0.86-0.91), and late post-PCV13 0.75 (95% CI 0.73-0.78). The AOM IRs declined during the 2003-2019 period; however, the clinical burden of AOM remains substantial among children ≤17 years in England.
Sections du résumé
BACKGROUND
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2006 and the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010 in the UK. PCVs are active immunization for the prevention of invasive disease, pneumonia and acute otitis media (AOM) caused by Streptococcus pneumoniae in children. The aim of this observational study was to estimate incidence rates (IRs) of AOM in children ≤17 years from 2003 to 2019 in England, before and after the introduction of pneumococcal conjugate vaccines (PCVs).
METHODS
AOM episodes were identified using Read diagnosis codes in children aged ≤17 years in the Clinical Practice Research Datalink (CPRD) Gold database from 2003 to 2019. Annual IRs with 95% confidence intervals (CI) by age group were calculated as the number of episodes/person-years (PY) at risk. Interrupted time series analyses were conducted to estimate incidence rate ratios (IRR) across post-PCV7 (2007-2009), early post-PCV13 (2011-2014) and late post-PCV13 (2015-2019) periods compared to the pre-PCV7 period (2003-2005) using generalized linear models.
RESULTS
From 2003 to 2019, 274,008 all-cause AOM episodes were identified in 1,500,686 children. The overall AOM IR was 3690.9 (95% CI 3677.1-3704.8) per 100,000 PY. AOM IRs were highest in children aged < 5 years and decreased by age; < 2 years: 8286.7 (95% CI 8216.8-8357.1); 2-4 years: 7951.8 (95% CI 7902.5-8001.4); 5-17 years: 2184.4 (95% CI 2172.1-2196.8) (per 100,000 PY). Overall AOM IRs declined by 40.3% between the pre-PCV7 period and the late-PCV13 period from 4451.9 (95% CI 4418.1-4485.9) to 2658.5 (95% CI 2628.6-2688.7) per 100,000 PY, and across all age groups. IRRs indicated a significant decrease in AOM IRs in all the post-vaccination periods, compared to the pre-PCV7 period: post-PCV7 0.87 (95% CI 0.85-0.89), early post-PCV13 0.88 (95% CI 0.86-0.91), and late post-PCV13 0.75 (95% CI 0.73-0.78).
CONCLUSIONS
The AOM IRs declined during the 2003-2019 period; however, the clinical burden of AOM remains substantial among children ≤17 years in England.
Identifiants
pubmed: 36717794
doi: 10.1186/s12889-023-14982-8
pii: 10.1186/s12889-023-14982-8
pmc: PMC9885604
doi:
Substances chimiques
Vaccines, Conjugate
0
Pneumococcal Vaccines
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
201Informations de copyright
© 2023. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
Références
Prim Care. 2014 Mar;41(1):11-8
pubmed: 24439877
Int J Epidemiol. 2013 Aug;42(4):1187-95
pubmed: 23760528
Arch Dis Child. 2022 Dec;107(12):1088-1094
pubmed: 35948405
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
PLoS One. 2012;7(4):e36226
pubmed: 22558393
BMC Infect Dis. 2016 Aug 11;16(1):407
pubmed: 27514843
BMC Pediatr. 2017 Jan 5;17(1):3
pubmed: 28056896
Nat Rev Dis Primers. 2016 Sep 08;2:16063
pubmed: 27604644
BMC Pediatr. 2022 Apr 13;22(1):204
pubmed: 35418046
BMC Med. 2018 Feb 8;16(1):13
pubmed: 29415741
PLoS One. 2016 Mar 08;11(3):e0150949
pubmed: 26953891
BMJ Open. 2020 May 5;10(5):e035343
pubmed: 32371515
Pediatrics. 2004 May;113(5):1451-65
pubmed: 15121972
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Pediatrics. 2013 Mar;131(3):e964-99
pubmed: 23439909
Hum Vaccin Immunother. 2021 Feb 1;17(2):517-526
pubmed: 32574101
Int J Pediatr Otorhinolaryngol. 2013 Aug;77(8):1231-6
pubmed: 23746414
Int J Pediatr Otorhinolaryngol. 2017 Oct;101:249-253
pubmed: 28964304
Pediatr Infect Dis J. 1994 Sep;13(9):765-8
pubmed: 7808842
BMC Pediatr. 2012 Nov 29;12:185
pubmed: 23190626
Pathogens. 2020 May 21;9(5):
pubmed: 32455770
Br J Gen Pract. 2017 Jan;67(654):e29-e40
pubmed: 27993900
BMJ Open. 2020 Jun 22;10(6):e038767
pubmed: 32571866
J Pediatr. 2021 Aug;235:233-238.e3
pubmed: 33894263
Value Health. 2022 Jun;25(6):1042-1056
pubmed: 35667776
BMC Infect Dis. 2022 Mar 26;22(1):294
pubmed: 35346092
Vaccine. 2015 Sep 22;33(39):5072-9
pubmed: 26297875
PLoS One. 2018 Dec 18;13(12):e0209048
pubmed: 30562385
Vaccine. 2021 May 6;39(19):2628-2635
pubmed: 33858719
Otolaryngol Clin North Am. 2014 Oct;47(5):651-72
pubmed: 25213276
Lancet. 2004 Feb 7;363(9407):465-73
pubmed: 14962529
Lancet Child Adolesc Health. 2018 Aug;2(8):561-568
pubmed: 30119715
An Pediatr (Barc). 2004 Feb;60(2):133-8
pubmed: 14757016